PT  - JOURNAL ARTICLE
AU  - E. Jewell
AU  - A. A. Secord
AU  - T. Brotherton
AU  - A. Berchuck
TI  - Use of trastuzumab in the treatment of metastatic endometrial cancer
AID  - 10.1136/ijgc-00009577-200605000-00064
DP  - 2006 Apr 01
TA  - International Journal of Gynecologic Cancer
PG  - 1370--1373
VI  - 16
IP  - 3
4099  - http://ijgc.bmj.com/content/16/3/1370.short
4100  - http://ijgc.bmj.com/content/16/3/1370.full
SO  - Int J Gynecol Cancer2006 Apr 01; 16
AB  - Systemic therapy of metastatic endometrial cancer is relatively ineffective. Response rates to chemotherapy and hormonal therapy in published studies range from 11% to 57%, but most responses are partial and of limited duration. In this case, we present a 76-year-old woman with stage IIIA endometrial adenocarcinoma who was initially treated with surgery and pelvic radiation. She developed multiple pulmonary metastases. She was treated with weekly paclitaxel chemotherapy. Immunostaining revealed that the primary endometrial cancer overexpressed HER-2/neu. Trastuzumab was added to the regimen, and a dramatic partial response was achieved. After a second pulmonary relapse following discontinuation of prior therapy, she was again successfully treated with trastuzumab in combination with paclitaxel and then docetaxel. Therefore, trastuzumab may be a useful adjuvant to taxane-based chemotherapy in some patients with metastatic endometrial cancers that overexpress HER-2/neu.